The United States Patent and Trademark Office (USPTO) has just granted to Solubest a new US Patent describing an enabling platform Solumer proprietary technology to improve bio-availability of lipophilic crystalline drugs formulation technologies, namely; US Patent 9,254,268, entitled “Compositions comprising lipophilic active compounds and method for their preparations". Notably, Solubest was granted by USPTO extension exclusivity period for patent protection in addition to standard twenty years.
SoluBest selected for MIXIII start up pavilion technology presentation, May 2014
We are proud to announce that Solubest abstract was selected for two visibility events during the Israel Innovation conference (Tel Aviv Fairgrounds May 20-22, 2014) :
A. Participation in the Startup Pavilion Competition. This includes a 7 minute presentation, appearance in the conference catalog, and a complementary company booth. SoluBest was selected to the pavilion out of dozens of compating companies by the Innovation Steering Committee... Come meet us there!
SoluBest will present its portfolio of formulation technologies which are available to our custom formulation clients.
B. Company Presentation - May 22nd, at 3:30pm (Hall K). Please come and support!
We look forward to meeting you!
Drug Delivery and Formulation Conference
Solubest presented its technology and products at the BioMed 2012 Conference, in Israel
SoluBest and Dr. Reddy´s Sign Drug Delivery Collaboration to Develop New, Proprietary Formulations
Ness Ziona, October 4, 2010 -- SoluBest, a company developing an easy-to-integrate technological platform for solving the problem of drug insolubility, has closed a collaboration agreement with Dr. Reddy's Laboratories Ltd. (Hyderabad, India) to develop a new, proprietary formulation of one of SoluBest’s pipeline compounds. In return, SoluBest is eligible to upfront, research and milestone and significant royalty payments. Further financial details have not been disclosed.
SoluBest CEO presented at Medica and Ernst & Young's JOURNEY 2010 Conference, October 26th, Tel Aviv, Israel
SoluBest presented at Bio-Partnering Europe, Oct. 10-12th, London.
Dr. Yoram Sela, Dr. Phil Smith and Dr. Blair West join SoluBest's Scientific Advisory Board in 2010
SoluBest is featured in the Oral Delivery issue of ON Drug Delivery 2010.
Dr. John Siebert and Dr. Rodney Kasan join SoluBest's board of directors.
SoluBest is featured in a current issue of Drug Delivery Technology magazine.
SoluBest recently partnered with Belarus' Rubicon to test its latest formulation - Albendazole
SoluBest recently completed pre-clinical testing of its latest formulation for Albendazole in pigs. Conducted in conjunction with Belarus' Rubicon Pharmaceuticals, the trial involved the testing of SoluBest's formulation in over 40 animals. The results indicate SoluBest's formulation not only significantly exceeded commercial formulations' bio-availability, but that this was translated to markedly increased efficacy, with 100% elimination of infection within 7 days of administration.
SoluBest has recently completed a clinical bio-availability trial on its Nano-Resveratrol formulation .
Carried out in recent months, the trial involved 12 healthy volunteers on whom SoluBest's latest formulation for Resveratrol (shown in our technology section as SoluDrug 2) was tested. The trial took place at the Soroka Medical Center under the supervision of Prof. Avraham Danon. Final results that indicate SoluBest's formulation exhibited excellent bio-availability of this compound.